Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?

被引:199
|
作者
Otocka-Kmiecik, Aneta [1 ]
Mikhailidis, Dimitri P. [2 ]
Nicholls, Stephen J. [3 ]
Davidson, Michael [4 ]
Rysz, Jacek [5 ]
Banach, Maciej [1 ]
机构
[1] Med Univ Lodz, Chair Nephrol & Hypertens, Dept Hypertens, PL-90549 Lodz, Poland
[2] UCL, Sch Med, Dept Clin Biochem, London, England
[3] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44106 USA
[4] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA
[5] Med Univ Lodz, Chair Nephrol & Hypertens, Dept Nephrol Hypertens & Family Med, PL-90549 Lodz, Poland
关键词
Dyslipidemia; High density cholesterol; Inflammation; Lipids; Therapy; HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; CHOLESTERYL ESTER TRANSFER; TRANSFER PROTEIN-INHIBITION; ELEVATED OXIDATIVE STRESS; TYPE-2; DIABETIC-PATIENTS; ACUTE CORONARY SYNDROMES; HIGH-RISK; ANTIINFLAMMATORY PROPERTIES; ANTIOXIDANT PROPERTIES;
D O I
10.1016/j.plipres.2012.03.003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
High density lipoprotein (HDL) has many properties, which contribute to its atheroprotective role. However, some recent clinical trials have identified subjects with the progression of atherosclerosis despite normal levels of HDL cholesterol. This raises the question if all subfractions of HDL have the same properties. Moreover, recent investigations have shown that both acute and chronic inflammation may lead to structural and functional changes of HDL, which render the particles proinflammatory. Although therapeutic agents that increase HDL levels are now quite well established it is not clear whether they influence HDL quality. We review the current state of knowledge on the properties of HDL and factors/therapeutic agents which may restrain the transformation of normal HDL into dysfunctional HDL (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:314 / 324
页数:11
相关论文
共 50 条
  • [21] Correction: HDL as a target in the treatment of atherosclerotic cardiovascular disease
    Patrick Linsel-Nitschke
    Alan R. Tall
    Nature Reviews Drug Discovery, 2005, 4 : 698 - 698
  • [22] Congestion is an important diagnostic and therapeutic target in heart failure
    Gheorghiade, Mihai
    Shin, David D.
    Thomas, Tarita O.
    Brandimarte, Filippo
    Fonarow, Gregg C.
    Abraham, William T.
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2006, 7 : S12 - S24
  • [23] Cardiovascular Disease in South Asian Immigrants: a Review of Dysfunctional HDL as a Potential Marker
    Dod, Rohan
    Rajendran, Aishwarya
    Kathrotia, Mayuri
    Clarke, Amanda
    Dodani, Sunita
    JOURNAL OF RACIAL AND ETHNIC HEALTH DISPARITIES, 2023, 10 (03) : 1194 - 1200
  • [24] Cardiovascular Disease in South Asian Immigrants: a Review of Dysfunctional HDL as a Potential Marker
    Rohan Dod
    Aishwarya Rajendran
    Mayuri Kathrotia
    Amanda Clarke
    Sunita Dodani
    Journal of Racial and Ethnic Health Disparities, 2023, 10 : 1194 - 1200
  • [25] Clonal haematopoiesis in cardiovascular disease: prognostic role and novel therapeutic target
    Schuermans, Art
    Honigberg, Michael C.
    NATURE REVIEWS CARDIOLOGY, 2025,
  • [26] High-density lipoproteins: a novel therapeutic target for cardiovascular disease
    Saleem, T. S. Mohamed
    Rani, P. V. Sandhya
    Gauthaman, K.
    RESEARCH REPORTS IN CLINICAL CARDIOLOGY, 2011, 2 : 1 - 6
  • [27] L-Arginine transporters in cardiovascular disease: A novel therapeutic target
    Chin-Dusting, J. P. F.
    Willems, L.
    Kaye, D. M.
    PHARMACOLOGY & THERAPEUTICS, 2007, 116 (03) : 428 - 436
  • [28] Circadian system A novel diagnostic and therapeutic target in Parkinson's disease?
    Videnovic, Aleksandar
    Willis, Gregory L.
    MOVEMENT DISORDERS, 2016, 31 (03) : 260 - 269
  • [29] Lipoprotein(a) as a therapeutic target in cardiovascular disease
    Koschinsky, Marlys
    Boffa, Michael
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2014, 18 (07) : 747 - 757
  • [30] INFLAMMATION AS A THERAPEUTIC TARGET IN CARDIOVASCULAR DISEASE
    Ritchie, R.
    CARDIOLOGY, 2015, 132 : 32 - 32